Literature DB >> 8598690

The quality of cost data. A caution from the Department of Veterans Affairs experience.

R W Swindle1, M C Beattie, P G Barnett.   

Abstract

Many health care system, including that of the Department of Veterans Affairs (VA), are facing dramatic changes as they adapt to state-level reform legislation and move into managed care environments. As new costing systems are designed and as researchers seek to conduct cost-effectiveness studies to guide health policy, it is critical to examine the assumed validity of the measurement procedures on which these costing systems are based. The foundation for VA health care costing is the cost distribution report, which is created by combining data on expenditures and workload with local service chiefs' estimates of program staffing and resource use. To evaluate the accuracy of the cost distribution report, the authors compared data from the report to cost data obtained in three multisite studies. Substantial differences were found between the cost distribution report and these independent sources, suggesting that researchers should not place uncritical reliance on the cost distribution report. The accuracy of costing data in information systems being implemented by VA will be limited to the extent they rely on the existing VA cost distribution system. Several strategies can be used in studies with a cost component to compensate for imperfect cost distribution systems.

Mesh:

Year:  1996        PMID: 8598690     DOI: 10.1097/00005650-199603001-00008

Source DB:  PubMed          Journal:  Med Care        ISSN: 0025-7079            Impact factor:   2.983


  2 in total

1.  Cost-effectiveness of inpatient substance abuse treatment.

Authors:  P G Barnett; R W Swindle
Journal:  Health Serv Res       Date:  1997-12       Impact factor: 3.402

2.  The effect of cost construction based on either DRG or ICD-9 codes or risk group stratification on the resulting cost-effectiveness ratios.

Authors:  Elinor C G Chumney; Andrea K Biddle; Kit N Simpson; Morris Weinberger; Kathryn M Magruder; William N Zelman
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.